NASDAQ:HGEN - Humanigen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $25.57
  • Forecasted Upside: 353.39 %
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$5.64
▼ -0.1 (-1.74%)

This chart shows the closing price for HGEN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Humanigen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HGEN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HGEN

Analyst Price Target is $25.57
▲ +353.39% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Humanigen in the last 3 months. The average price target is $25.57, with a high forecast of $35.00 and a low forecast of $9.00. The average price target represents a 353.39% upside from the last price of $5.64.

This chart shows the closing price for HGEN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Humanigen. This rating changed within the last month from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/14/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/13/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/13/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 1 sell ratings
11/8/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings
12/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2021Cantor FitzgeraldReiterated RatingOverweightHigh
10/8/2021JPMorgan Chase & Co.DowngradeSellMedium
9/10/2021Jefferies Financial GroupDowngradeBuy ➝ Hold$37.00 ➝ $9.00High
9/9/2021Credit Suisse GroupDowngradeOutperform ➝ NeutralHigh
9/9/2021HC WainwrightLower Price TargetBuy$36.00 ➝ $28.00High
9/9/2021JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
8/13/2021Credit Suisse GroupLower Price TargetOutperform$25.00 ➝ $24.00Low
8/10/2021Roth CapitalLower Price TargetBuy$37.00 ➝ $32.00High
8/4/2021OppenheimerReiterated RatingOutperform$30.00Low
7/9/2021Jefferies Financial GroupReiterated RatingBuy$40.00Low
7/9/2021HC WainwrightReiterated RatingBuy$36.00Medium
6/11/2021Credit Suisse GroupInitiated CoverageOutperform$28.00Low
5/6/2021OppenheimerInitiated CoverageOutperform$30.00Medium
5/5/2021Roth CapitalBoost Price TargetBuy$35.00 ➝ $37.00Medium
4/19/2021HC WainwrightReiterated RatingBuy$34.00 ➝ $36.00High
4/12/2021HC WainwrightBoost Price TargetBuy$34.00 ➝ $36.00High
3/29/2021Roth CapitalBoost Price TargetBuy$25.00 ➝ $35.00High
2/23/2021JPMorgan Chase & Co.Initiated CoverageNeutral$21.00High
12/23/2020National SecuritiesInitiated CoverageBuy$35.00N/A
12/22/2020Jefferies Financial GroupInitiated CoverageBuy$27.00Low
11/6/2020HC WainwrightBoost Price TargetPositive ➝ Buy$31.00 ➝ $34.00Medium
11/6/2020HC WainwrightReiterated RatingPositive ➝ Buy$31.00 ➝ $34.00High
10/21/2020Cantor FitzgeraldReiterated RatingOverweight$25.00Medium
10/20/2020Cantor FitzgeraldInitiated CoverageOverweight$25.00Medium
10/14/2020HC WainwrightReiterated RatingBuy$31.00High
10/14/2020HC WainwrightInitiated CoverageBuy$31.00High
10/1/2020Roth CapitalInitiated CoverageBuy$25.00High
9/30/2020Roth CapitalReiterated RatingBuyHigh
(Data available from 12/9/2016 forward)

News Sentiment Rating

0.12 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/13/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2021
  • 1 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2021
  • 5 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
8/11/2021
  • 1 very positive mentions
  • 12 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
9/10/2021
  • 3 very positive mentions
  • 24 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/10/2021
  • 10 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
11/9/2021
  • 1 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/9/2021

Current Sentiment

  • 1 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Humanigen logo
Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is based in Burlingame, California.
Read More

Today's Range

Now: $5.64
Low: $5.45
High: $5.81

50 Day Range

MA: $6.41
Low: $5.31
High: $8.22

52 Week Range

Now: $5.64
Low: $5.04
High: $29.20

Volume

902,306 shs

Average Volume

1,972,043 shs

Market Capitalization

$359.93 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Humanigen?

The following equities research analysts have issued reports on Humanigen in the last twelve months: Cantor Fitzgerald, Credit Suisse Group AG, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., National Securities, Oppenheimer Holdings Inc., Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for HGEN.

What is the current price target for Humanigen?

7 Wall Street analysts have set twelve-month price targets for Humanigen in the last year. Their average twelve-month price target is $25.57, suggesting a possible upside of 360.7%. National Securities has the highest price target set, predicting HGEN will reach $35.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $9.00 for Humanigen in the next year.
View the latest price targets for HGEN.

What is the current consensus analyst rating for Humanigen?

Humanigen currently has 1 sell rating, 2 hold ratings and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HGEN will outperform the market and that investors should add to their positions of Humanigen.
View the latest ratings for HGEN.

How do I contact Humanigen's investor relations team?

Humanigen's physical mailing address is 533 Airport Boulevard Ste. 400, Burlingame CA, 94010. The official website for Humanigen is www.humanigen.com.